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NefPrevious studies demonstrated that the nef gene is a critical determinant of the pathogenicity of simian
immunodeﬁciency virus (SIV) in macaques. In the present study, we evaluated the effect of a spontaneous
frameshift mutation in the C-terminus of the nef gene of the minimally pathogenic SIVsmH4i clone. This
clone exhibited a single nucleotide deletion in the nef gene relative to pathogenic SIV clones that resulted in a
frameshift and addition of 46 amino acids to the C-terminus of Nef. We generated a corrected version of this
clone, SIVsmH4i Nef+ that restored Nef protein expression. Inoculation of macaques with SIVsmH4i resulted
in delayed and low levels of peak viremia. This contrasted with improved kinetics and robust peak viremia in
macaques inoculated with the corrected version. Despite the restoration of in vivo replication ability, neither
clone resulted in memory CD4+ T cell loss or disease in a period of two years.r Drive, Bldg 4, Room B1-41,
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Simian immunodeﬁciency virus (SIV) infection of macaques has
become a valuable surrogate model for human AIDS (Daniel et al.,
1985) for vaccine and pathogenesis studies. SIVs originating from
sooty mangabey monkeys (both SIVsm and SIVmac) are the most
widely used for vaccine studies. However, there is a relative paucity
of pathogenic SIV clones from the sooty mangabey lineage for evalua-
tion of vaccine efﬁcacy. In addition, many of these viruses such as
SIVmac239 and SIVsmE543-3 are difﬁcult to neutralize; therefore
they are more reﬂective of viruses at the most resistant end of
the spectrum of primary HIV isolates. The development of alternative
SIV strains with greater sensitivity to neutralization, but retaining
pathogenicity, would be useful for the evaluation of vaccine strategies
intended to induce neutralizing antibody responses.
Our lab has focused on a lineage of SIV originally derived from
a naturally SIVsm-infected sooty mangabey, E038 that was subse-
quently passaged in a rhesus macaque, F236 (Baskin et al., 1988).
Virus isolated in H9 cells from PBMC at the time that F236 developed
AIDS was used to generate the ﬁrst molecular clone of SIVsm (Hirschet al., 1989b) and in subsequent animal passages to generate more
pathogenic virus strains. SIVsmH4 has been the basis for immunogens
in a number of vaccine studies (Hirsch et al., 1996; Moss et al., 1996;
Ourmanov et al., 2000a,b; Sharpe et al., 2001). The original proviral
clone had a spontaneous frameshift mutation in the integrase domain
of pol that impaired virus replication in vitro but was corrected by
mutagenesis to generate SIVsmH4i. Despite robust replication in vitro,
SIVsmH4i was minimally pathogenic in macaques (Hirsch et al.,
1989a) resulting in extremely low primary and often undetectable
post-acute viremia. This contrasted with the robust replication and
pathogenicity of the closely related SIVsmE543-3 clone (Hirsch et al.,
1997; Kuwata et al., 2007) that was derived from passage of
SIVsmF236 in a rhesus macaque, E543. These clones also differ in a
number of biologic properties that are related to differences in their
envelope genes. Thus SIVsmH4i does not infect macaque monocyte
derived macrophages (MDM) in vitro and is extremely sensitive to
neutralizing antibody whereas SIVsmE543-3 replicates in MDM and is
much more difﬁcult to neutralize (Hirsch et al., 1997). Comparative
analysis of nef gene sequences relative to other SIVsm/mac clones
revealed a single nucleotide deletion at position 761 of SIVsmH4i
nef gene, which results in a frameshift and the addition of 46 amino
acids to the C-terminus of Nef (see Fig. 1).
Previous studies have demonstrated that HIV or SIV Nef is one of
the major determinants of virulence (Kestler et al., 1991; Kirchhoff
et al., 1995, 2008). Nef is a small myristoylated protein devoid of
enzymatic activity. It is mainly localized in the paranuclear region
with reduced expression at the plasma membrane and serves as an
adaptor protein to divert host cell proteins to aberrant functions that
Fig. 1. Comparison of nucleotide (A) and amino acid (B) sequences of the C-terminus of Nef of the original SIVsmH4i, the corrected version and sequences found at various time
points post-infection inmacaques H729. The nucleotide sequence of the original clone at the top is alignedwith nucleotide substitutions below and identical nucleotides indicated by
a dash (-). Gaps are indicated by a dot (.). The amino acid sequence of the C-terminus of Nef is shown in single amino acid code using the same symbols.
Fig. 2. Western blot analysis of the Nef protein expression in SIVsmH4i and SIVsmH4I
Nef+-transfected 293T cells. A. Western blotting with RhE544 anti-SIV serum, demon-
strates a 32 kDa protein consistent with the size of Nef in both SIVsmH4i Nef+ and
SIVmac239 infected cells expressing Nef protein. A comparable but larger molecular
weight species cannot be identiﬁed in SIVsmH4i-transfected cells. B. SIVsmH4i,
SIVsmH4in, and SIVmac239 infected 293T cell lysate western blotting with anti-
SIVmac251 Nef monoclonal antibody, which only recognizes SIVmac239 Nef protein,
conﬁrms that the 32 kDa protein expressed in panel A is indeed Nef.
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Nef regulates multiple host factors in order to optimize the cellular
environment for virus replication (Foster and Garcia, 2008). Four
in vitro functions common to both HIV and SIV Nefs are: 1) down-
regulation of cell surface levels of CD4 (Garcia and Miller, 1991;
Lundquist et al., 2002); 2) down-regulation of surface levels of major
histocompatibility class I (MHC-I) molecules (Atkins et al., 2008;
Schwartz et al., 1996); 3) mediation of cellular signaling and
activation (Wei et al., 2005); and 4) enhancement of viral particle
infectivity by CD4 independent mechanisms (Campbell et al., 2004;
Pizzato et al., 2007). However, for many years considered as an
ampliﬁer of HIV replication, the functions of Nef are far more complex.
In T cells, Nef could be viewed as a T cell receptor-associated adaptor
protein exerting a number of speciﬁc signaling functions through
the assembly of multi-protein complexes (Arien and Verhasselt,
2008). By targeting the T cell receptor (TCR), Nef may not only prime
viral replication but, more importantly, ensure viral survival through
distinct mechanisms of immune evasion and anti-apoptosis (Arrode
et al., 2008). Recent studies have suggested that SIV Nef may have
Vpu-like activity in overcoming the inhibitory activity of tetherin
(Jia et al., 2009).
The majority of SIV Nef mutations that have been studied have
been the result of premature stop codons or internal deletions, thus
resulting in a truncated Nef protein. In contrast, this particular
mutationwas unique in that themajority of the nef reading framewas
intact but was fused to an irrelevant sequence at the C-terminus. This
particular mutation was in a region that did not overlap envelope and
thus did not affect any other open reading frames. To assess the role of
this particular mutation in the attenuated phenotype of SIVsmH4i, we
corrected the mutation to generate SIVsmH4i Nef+ and investigated
its replication and pathogenicity in rhesus macaques.
Results
To evaluate the impact of this unique nef mutation in SIV patho-
genesis, we inserted an “A” at position 761 in nef of SIVsmH4i by
PCR mutagenesis (Fig. 1A) to exactly replicate the sequence found in
both SIVmac239 and SIVsmE543-3. The resulting clone designated
SIVsmH4i Nef+ was isogenic to the parental strain in all other genes.
Following transfection of 293T cells, both viruses generated similar
levels of reverse transcriptase activity (data not shown). As shown in
Fig. 2, similar levels of viral proteins were observed by western blot
analysis of transfected cells using plasma from a SIV-infected rhesus
macaque E544 for detection. The major difference between the
protein proﬁles was the absence of a viral protein of approximately
32 kDa in the SIVsmH4i-transfected cells relative to SIVsmH4i Nef+.
This protein co-migrated with a similar protein in SIVmac239-
transfected cells in the predicted size range of the SIV Nef protein.
Since there are no anti-sera speciﬁc for SIVsm Nef protein, we used
antiserum to SIVmac251 Nef to identify this protein as Nef in
SIVmac239-transfected cells (Fig. 2B). As expected, the 32 kDa proteinof SIVmac239 reacted with the Nef antibody. Due to signiﬁcant
differences in the sequence of SIVsmH4i Nef, this antiserum did not
react with Nef in SIVsmH4i Nef+-transfected cells. The size of Nef in
SIVsmH4i would be predicted to be at least 5 kDa larger than proto-
typic Nef. However, this larger molecular weight species was not
identiﬁed in SIVsmH4i-transfected cells (Fig. 2A). We presume that
the absence of Nef expression is the result of instability resulting from
the additional amino acids on the C-terminus.
Correction of the Nef mutation restores Nef protein function
The relative replication ability of SIVsmH4i Nef+ and SIVsmH4i
viruses, normalized for reverse transcriptase (RT) activity of input
virus, was compared in CEMx174 cells and macaque PBMCs in vitro
(Fig. 3). Both viruses replicated relatively efﬁciently with similar
kinetics. To evaluate whether these viruses differed in terms of any
Fig. 3. Comparison of replication of SIVsmH4i and SIVsmH4i Nef+ in CEMx174 cells and
PBMCs in vitro. A. SIVsmH4i Nef+ virus replicated more efﬁciently than the parental
SIVsmH4i virus in CEMx174 cells (Pb0.05). B. SIVsmH4i Nef+ virus replicated more
efﬁciently than the parental SIVsmH4i virus in rhesus PBMC cells (Pb0.05).
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infection with SIVsmH4i and SIVsmH4i Nef+ on the expression of
CD4 and MHC Class I on a genetically engineered clone of CEMx174
cells — 5.25.EGFP.Luc.M7, that express multiple entry receptors and
co-receptors for SIV. The M7-Luc cells also express the enhanced
green ﬂuorescent protein gene under a Tat-responsive promoter
allowing us to gate on infected cells to evaluate whether they down-
regulated these cell surface proteins. As shown by ﬂow cytometric
analysis of M7-Luc cells infection in Fig. 4, SIVsmH4i Nef+ clearly
down-regulated MHC-I molecules (Fig. 4, left panels) whereas the
original SIVsmH4i had no effect on MHC-I expression levels. The
extent of down-regulation was similar to that observed for the
pathogenic clone, SIVsmE543-3. The picture was more complex
with CD4 expression since envelope expression alone can induce
CD4 down-regulation. Thus both viruses induced down-regulation of
CD4, however, CD4 down-regulation was more profound in cells
infected with SIVsmH4i Nef+, similar in extent to that observed with
SIVsmE543-3 (Fig. 4, right panels).
Correction of the Nef mutation restores in vivo virus replication
Finally, to evaluate viral replication and pathogenicity in vivo, two
groups of four rhesus macaques each were inoculated intravenously
with 5000 TCID50 of SIVsmH4i or SIVsmH4i Nef+. Macaques were
monitored sequentially for viral replication by plasma viral RNA
(Fig. 5A) and effects on peripheral CD4+ T cells by ﬂow cytometry
(Figs. 5B and C). Macaques inoculated with SIVsmH4i Nef+ demon-
stratedpeakplasmaviral RNA levels of 104 to 106 copies perml between
14 and 21 days post-inoculation followed by persistent but low levels of
plasma viremia (102 to 104) for the remaining course of the infection
(Fig. 5A). This contrastedwith a delayedpeak of viremia frombetween4
and 12 weeks p.i. in macaques inoculated with the parental SIVsmH4i.Due to the delay and decreasedmagnitude of viremia, plasma viral RNA
levels were signiﬁcantly lower in macaques infected with SIVsmH4i at
2 and 3 weeks (Mann Whitney U, P=0.028). Peak plasma viral RNA
levels were also considerably lower in these animals, ranging from
103 to 104, with one exception, macaque, H729. Two macaques had
undetectable viremia (b100 copies/ml) during the chronic phase of
infection (H724 and H710). Indeed, one of these macaques only
exhibited detectable plasma viremia at one time point (12 weeks p.i).
There was a trend to lower viral load in the group inoculated with
SIVsmH4i throughout the chronic phase of infection (MannWhitney U,
P=0.057).
Spontaneous correction of the Nef mutation in one macaque
A single nucleotide change in the original SIVsmH4i could result in
correction of the nef frameshift. This was of particular interest in
macaque H729 from the SIVsmH4i group that exhibited higher viral
load. We therefore evaluated a portion of nef ampliﬁed by RT-PCR
from plasma viral RNA at various time points during infection in each
of the animals with the exception of the animal with undetectable
viremia, H724. Direct sequencing of the products revealed the appro-
priate virus sequence in each of the animals at early time points.
When compared with the SIVsmH4i inoculum, the correct sequence
was detected in plasma of H729 at 3 weeks but was completely re-
placed with a variant with a single “T” insertion by 6 weeks p.i.
(Fig. 1A). This mutation was associated with increasing virus load
(arrow in Fig. 5A). The virus in this animal was not identical to
SIVsmH4i Nef+ due to an additional substitution at position 762,
resulting in a Leu to Tyr substitution at amino acid 252 of Nef (Fig. 1B).
Thus, the increase in plasma viremia corresponded to the appearance
of a reversion of the nef frameshift mutation. The original mutation
was stable in the other three macaques in the SIVsmH4i group until at
least 40 weeks p.i., the last time point evaluated. If rhesus macaque
H729 is excluded from comparison of viral load, a signiﬁcant and
sustained increase in plasma viremia at both peak and setpoint was
observed in macaques inoculated with the SIVsmH4i Nef+ virus
(Fig. 6; Mann Whitney, Pb0.0001).
Infection with SIVsmH4i Nef+ results in slow CD4+ T cell depletion
Whole blood samples from the eight rhesus macaques were
analyzed sequentially for CD4+ T cell levels by ﬂow cytometry. As
shown in Fig. 5B, a transient decline in CD4+ T cell levels was
observed during primary viremia. Subsequently, the CD4+ T cell
levels remained relatively stable in both groups of macaques. Analysis
of memory CD4+ T cell subsets in the blood did not reveal signiﬁcant
changes in this subset and a transient decline in CD4+ T cells in
bronchoalveolar lavage (BAL) was only observed in the macaque with
highest peak viremia (H727) (data not shown). Since the absolute
pre-inoculation CD4+ T cell counts varied widely between individual
macaques, we also evaluated the percent of CD4+ T cell remaining as
compared to pre-inoculation values (Fig. 5C). The SIVsmH4i group
maintained higher percentage of CD4+ T cells than SIVsmH4iNef+
group (Fig. 6, MannWhitney U, P=0.04), consistent with lowermean
viral RNA load observed in these animals. Data analyses that excluded
the one SIVsmH4i macaque with reversion of the Nef mutation gave
very similar results (data not shown). The study was terminated at 60
and 84 weeks post-inoculation and at that time point, CD4+ T cell
numbers remained above AIDS-deﬁning levels and there was no
evidence of clinical immunodeﬁciency in any of the macaques and no
signiﬁcant ﬁndings were observed on pathologic examination.
Despite improved in vivo replication, SIVsmH4in was still less robust
than the closely related pathogenic, neutralization-resistant
SIVsmE543-3 (Goldstein et al., 2000; Hirsch et al., 1997) as evidenced
by lower chronic phase viremia (Fig. 6A) and CD4+ T cell decline
(Fig. 6B).
Fig. 4. Comparison of the ability of SIVsmH4i and SIVsmH4iNef+ to down-regulate MHC-I and CD4 on cell surface following infection of M7-Luc cells. M7-Luc cells were infected
with SIVsmH4i, SIVsmH4iNef+ or SIVsmE543-3 in triplicate and tested at 68 h post-infection. To measure the level of MHC-I and CD4, cells were stained with anti-human CD4-APC,
7-AAD and HLA-A2-PE. Approximately 30,000 live infected cells (as determined by EGFP positive and 7-AAD negative gating) were counted by ﬂow cytometry and FACS histograms
of cell distribution for representative samples are shown in the upper panels. Themock-infectedM7-Luc cells were used to set theMHC-I and CD4 positive gates and infectedM7-Luc
cells stained with isotype control antibodies were used to set the negative gates. The lower panels show the percentage of cells which down-regulated MHC-I or CD4 molecules as
indicated by HLA-A2 low or CD4 low expression. The brackets on the graphs represent 95% CI and numbers represent the P value for the unpaired t-test comparingmeans of indicated
triplicates of cells infected with different SIVs.
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The kinetics of antibody responses was compared between the two
groups by western blot analysis. Overall, the antibody responses in
the SIVsmH4i groupwereweaker than observed in animals infectedwith
SIVsmH4i Nef+ (data not shown). We therefore evaluated the neutral-
izing antibody responses in the two groups. Serum samples collected at
20 weeks post-infection from both groups of macaques neutralized not
only homologous SIVsmH4i viruses, but also cross-neutralized the closely
related viruses, SIVsmE660 and SIVsmE543. These two viruses represent
slightly heterologous strains that are relatively sensitive and resistant to
neutralization respectively. Titers were consistently higher in the Nef-
corrected SIVsmH4iNef+group (Pb0.05, see Table 1), presumably due to
more robust virus replication.
Discussion
This study conﬁrms the importance of the Nef protein in SIV
pathogenesis. Correction of a unique nef frameshift mutation in the
attenuated SIVsmH4i, restored virus replication in vitro and in vivo.
Although the SIVsmH4i Nef was predicted to be signiﬁcantly larger in
molecularweight, analysis of cell lysates of cells transfectedwith this virus
found no evidence for either the wild type Nef protein or a larger species.
However, correction of the frameshift in SIVsmH4i Nef+ resulted in
expression of a Nef protein that co-migrated with the Nef protein of
SIVmac239. We assume therefore, that addition of nonsense amino acids
on the C-terminus of Nef results in instability or aberrant trafﬁcking and
degradation of the protein. Consistentwith that hypothesis, SIVsmH4i didnot induce down-regulation ofMHC-I antigens in infected cells and had a
reduced ability to down-regulate CD4 expression, both properties that
were intact for the corrected SIVsmH4i Nef+. These two properties map
to different regions of theNef protein, conﬁrming that the entire protein is
apparently not expressed in SIVsmH4i.
Most importantly, macaques inoculated with SIVsmH4i Nef+
exhibited higher peak viral load with normal kinetics and persistence
of level viremia during chronic infection. In contrast, macaques
infected with SIVsmH4i showed lower peak viral loads and delayed
kinetics of virus replication consistent with a Nef defect. There
was not a clear distinction in the pathogenicity of the two viruses.
However, macaques inoculated with the original SIVsmH4i main-
tained higher percentage of their CD4+ T cells than those inoculated
with SIVsmH4i Nef+, consistent with lower mean viral RNA load.
Consistent with higher viral replication, macaques inoculated with
SIVsmH4i Nef+ group had higher Nab titers than the macaques
inoculated with SIVsmH4i. The neutralizing phenotype of the two
viruses did not differ from one another. Therefore, SIVsmH4i Nef+
clearly replicates more efﬁciently which could be useful for SIV
pathogenesis and vaccine research.
SIVsmH4i Nef+ did not result in AIDS after 1 to 1.5 year of follow-up.
Based on the slowly declining CD4+ T cell counts, persistence of plasma
viremia and previous studies with the original SIVsmH4i clone in
macaques (Johnson et al., 1991), it is probable that this virus would
eventually result inAIDS after longer follow-up. The underlying reason for
the reduced virulence of this virus is not clear. The original SIVsmH4
lambda clonewas derived from a long term passage of SIVsmF2236 in H9
cells that apparently contributed to the two attenuatingmutations; these
Fig. 5. Comparison of plasma viremia and CD4 T cell counts in peripheral blood of SIVsmH4i (left panels) and SIVsmH4i Nef+ (right panels). A. Plasma viral RNA levels are shown
sequentially throughout infection of each of the macaques. B. Absolute CD4+ T cell numbers in peripheral blood are shown sequentially for all macaques. C. The percent of pre-
inoculation CD4+ T cells remaining at various time points after infection is shown.
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Although all other genes appear intact, this clone may have additional
attenuating mutations in other genes. Alternatively we have speculated
that theneutralizationphenotypemay result in avirus that ismore readily
controlled by neutralizing antibodies. Studies are underway to investigate
the pathogenicity of a SIVsmH4i Nef+ chimera expressing the E543-3
envelope to investigate this latter possibility.
Despite the lack of a clearly pathogenic phenotype, correction of
the Nef mutation restored primary virus replication to levels that
would allow its use in testing prophylactic strategies aimed at
preventing infection. In addition, infection with SIVsmH4i Nef+
clearly resulted in robust SIV-speciﬁc homologous and heterologous
neutralizing antibody titers. As antibodies act as a ﬁrst line of
defense against HIV infection, the elicitation of humoral immunity
should be a component of an effective HIV vaccine. The ability of
antibodies to confer protection against HIV has been demonstrated
by several studies using the passive transfer of neutralizing anti-
bodies in the non-human primate challenge model (Baba et al.,
2000; Eda et al., 2006; Nishimura et al., 2003; Veazey et al., 2003).
Efforts have been made to induce a similarly protective humoral
immune response by vaccination with antigens derived from HIV.
Thus far, the results have been disappointing. Humoral immune
responses elicited by vaccination display activities that are gener-
ally much less potent and broad as compared to those inducedduring natural infection (Burke and Barnett, 2007). Therefore,
more work is required to improve protective antibody responses
in non-human primate models. Our study provides a useful reagent
for vaccine research since virus from SIVsmH4in clone has a more
readily neutralizable envelope protein than many other more
pathogenic SIV strains.
Methods
QuickChange site-directed mutagenesis PCR
A 5 kb fragment of pSIVsmH4i digested with Hind III and Asp I
retaining nefwas religated after a Klenow ﬁll-in reaction to generate a
subclone for PCR mutagenesis. The QuickChange Site-Directed
Mutagenesis Kit (Stratagene, La Jolla, CA) was used according to the
manufacturer's instructions (Kunkel, 1985) to introduce an additional
“A” into the nef gene sequence using primers, 5′ GGC TAA CCG CAA
GAG GCC TTT ATA AAA TGG CTG ACA AGA AGG 3′ and 5′ CCT TCT TGT
CAG CCA TTT TAT AAA GGC CTC TTG CGG TTA GCC 3′ to replicate
the nucleotide sequence found in SIVmac239 and SIVsmE543-3.
The resulting clone was sequenced to conﬁrm themutation and a 1 kb
Nde I/Sal I fragment containing the mutation was used to replace
corresponding fragment into the full length pSIVsmH4i clone to create
pSIVsmH4iNef+.
Fig. 6. Sequential comparison of mean plasma viremia (A), absolute CD4+ T cell counts
(B) and percent CD4 cell remaining (C) in peripheral blood of SIVsmH4i (unﬁlled
squares) and SIVsmH4i Nef+ (black circles) inoculated macaques. Mean plasma
viremia (A) and CD4+ T cell counts (B) are also compared to a cohort of six SIVsmE543-
3-infected rhesus macaques (grey symbols), a fully pathogenic infection.
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The pSIVsmH4i and pSIVsmH4i Nef+ clones were transfected into
293T cells to generate cell free viruses using FuGENE transfection
reagent (Roche, Indianapolis, IN) according to the manufacturer'sTable 1
Magnitude and cross-reactivity of neutralizing antibodies detected 20 weeks post-
infection.
Nab titer
to SIVa
SIVsmH4i groupb SIVsmH4i Nef+ groupb
H724 H728 H710 H729 H726 H727 H715 H732
SIVsmH4i 450 488 388 437 2441 2729 2638 2483
SIVsmE660 433 459 391 428 2338 2655 2573 2429
SIVsmE543 57 64 51 62 326 349 337 329
a Values are the dilution or concentration at which RLU were reduced 50% compared
to those in virus control wells.
b Serum samples from each animals were obtained 20 weeks post-infection.instructions. Cell free supernatants from 293T transfected cells were
normalized for p27 antigen content and used to infect CEMx174 T
cells or macaque PBMC. Cells were incubated with virus for 2–3 h,
then pelleted and resuspended in fresh culture medium. Virus rep-
lication was detected by 32P reverse transcriptase (RT) assay as pre-
viously reported (Sears et al., 1999). PBMC were separated from
peripheral blood of healthy uninfected macaques by density centri-
fugation (LSM, ICN Biomedicals, Inc., Aurora, OH) according to the
manufacturer's instructions. PBMC were suspended in RPMI 1640,
supplemented with 10% human AB serum, penicillin (100 U/ml),
streptomycin (100 μg/ml) and 10% IL-2 at density of 106 cells/ml and
cultured with twice weekly media changes.
Western blot detection of Nef protein expression
Western blotting was performed to detect viral Nef protein
expression in 293T cells transfected with SIVsmH4i, SIVsmH4i Nef+
or SIVmac239. The cells were harvested at 72 h post transfection,
lysed with RIPA buffer (Upstate, Temecula, CA). Probes were heated
to 100 °C for 5 min in NuPAGE lithium dodecyl sulphate sample
buffer supplemented with NuPAGE reducing agent and subjected to
electrophoresis on aNuPAGE 4-12% Bis-Tris gel (Invitrogen, Carlsbad,
CA). MagicMark™ XP Western Protein Standard (Invitrogen, Carls-
bad, CA)was used asmolecular weightmarker. The resolved samples
were transferred to 0.2 μm nitrocellulose membrane using iBlot
transfer unit (Invitrogen, Carlsbad, CA) as suggested by the
manufacturer. Serum from a SIVsmF236-infected rhesus macaque,
E544 was used as a primary antibody for detection of viral proteins.
This antiserum reacts with the Env, Gag, Pol and Nef proteins of SIV.
To block non-speciﬁc binding the membrane was immersed in 5%
non-fat dried milk, 0.1% Tween 20 (Sigma, Saint Louis, MO) in Tris
buffered saline, pH7.6 (TBS-T) for 1 h at room temperature on an
orbital shaker. After blocking, the membrane was incubated with a
1:1000 dilution of the primary antibody the overnight, then brieﬂy
rinsed with two changes of wash buffer and washed 3 times for
10 min in TBS-T. After incubation with a 1:10,000 dilution of a sheep
anti-human Ig conjugated with horseradish peroxidase (Amersham,
Piscataway, NJ) for 1 h and intensive washing, proteins on the
membrane were detected by enhanced chemiluminescence with ECL
Plus Western Blotting Detection Reagent (Amersham, Piscataway,
NJ) A 1:500 dilution of SIVmac251 Nef speciﬁc monoclonal antibody
(17.2) as primary antibody and a sheep anti-mouse Ig horseradish
peroxidase conjugate (Amersham, Piscataway, NJ) as a secondary
antibody was used to detect SIVmac239 Nef. This monoclonal
antibody was obtained through the AIDS Research and Reference
Reagent Program, Division of AIDS, NIAID, NIH: SIVmac251 Nef
monoclonal antibody (17.2) from Dr. Kai Krohn and Dr. Vladimir
Ovod.
Animals and viruses
A total of eight juvenile, colony-bred, Indian-origin rhesus ma-
caques (Macaca mulatta) were randomly separated into two groups
and inoculated with either SIVsmH4i or SIVsmH4i Nef+ virus.
Animals were maintained in accordance with the guidelines of the
Committee on the Care and Use of Laboratory Animals under a NIAID-
approved animal study protocol and were housed in a Biosafety Level
2 facility using BSL3 practices. Virus stocks generated in 293T cells
were normalized by tissue culture infectious dose 50% (TCID50) on
TZM-bl cells in vitro. The animals were then inoculated intravenously
with 5000 TCID50 of the SIVsmH4i or SIVsmH4i Nef+ virus. EDTA-
coagulated blood samples were collected from macaques and moni-
tored sequentially for plasma viral RNA levels, CD4+ T cell subsets,
and SIV-speciﬁc neutralizing antibody titers. Bronchoalveolar lavages
(BAL) were collected sequentially for evaluating mucosal CD4+ T cell
depletion.
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Viral RNA was isolated from cryopreserved plasma samples using
the QIAamp Viral RNA Mini Kit (Qiagen, Hilden, Germany). Reverse
transcription was carried out using TaqMan reverse transcription
reagents (Applied Biosystems, Foster City, CA) and random RETRO-
script decamers (Ambion) for priming. Viral RNA levels in plasma
were then determined by quantitative real-time PCR using a Prism
7700 sequence detector (Applied Biosystems, Foster City, CA) as
detailed previously (Seth et al., 2000). A serial 5-fold dilution series of
the standard RNA template was assayed in duplicate to generate a
standard curve for each assay. RT-PCR for each plasma samples were
performed in triplicate including one control reaction processed
without addition of reverse transcriptase for potential DNA contami-
nation. Results of assay were normalized to the volume of plasma
extracted and expressed as SIV RNA copy equivalents per ml of
plasma, as described for HIV-1 (Piatak et al., 1993a,b). Interassay
variation was less than 25% (c.v.).
Sequence evaluation of the nef gene in infected macaques
To assess the stability of the frameshift mutation in macaques
infected with the original SIVsmH4i, nef sequences were ampliﬁed by
RT-PCR from plasma samples at different times post-infection. The
sequences of primers for nef gene RT-PCR used for ampliﬁcation were:
forward: 5′ ATG AAT ACC CCC TGG AGG AAC C 3′ and reverse: 5′ CTT
GTG GAA AGT CCC TGC TGT C 3′. Viral RNAwas extracted from plasma
using QIAamp Viral RNA Mini Kit (Qiagen, Valencia, CA) according to
the manufacturer's instructions and SuperScript III One-Step RT-PCR
Systemwith Platinum Taq DNA Polymerase (Invitrogen, Carlsbad, CA)
was used for RT-PCR. The products of RT-PCRwere sequenced directly
after puriﬁcation and sequence results were analyzed by Vector NTI
software.
Flow cytometric analysis
Blood, and mononuclear cells isolated from bronchoalevolar
lavage (BAL), and lymph node (LN) biopsies were stained with
combinations of the following ﬂuorochrome-conjugated monoclonal
antibodies: CD3 (ﬂuorescein isothiocyanate [FITC] or peridinin
chlorophyll protein-Cy5.5), CD4 (phycoerythrin [PE], peridinin chlo-
rophyll protein-Cy5.5, or allophycocyanin [APC]), CD28 (FITC), CD95
(APC), CCR5 (PE), CD8 (FITC or APC), CD8 beta (PE), CD20 (FITC or PE),
and mouse immunoglobulin G1 and G2 isotype-matched controls.
Percentages of memory/naïve cells in CD4+ T cells were determined
using CD28 and CD95 as makers, as described previously (Nishimura
et al., 2004).
The ability of Nef to down-regulate MHC-I and CD4 on infected
cells was assessed by infecting a genetically engineered clone of
CEMx174 cells, 5.25.EGFP.Luc.M7 (M7-Luc), that expresses mul-
tiple entry receptors and co-receptors for SIV (Monteﬁori, 2004).
The M7-Luc cells also express Tat-responsive reporter genes for ﬁreﬂy
luciferase and enhanced green ﬂuorescent protein (EGFP) that
allowing to gate on infected cells. M7-Luc cells were grown in
RPMI-1640 medium containing 2 mM L-glutamine, 25 mM HEPES,
10% heat-inactivated FBS and 50 μg/ml gentamycin. For routine
maintenance, cells were grown in medium supplemented with
0.2 mg/ml hygromycin B, 0.3 mg/ml genetecin (G418) and 0.5 μg/
ml puromycin. Supplemented drugs were removed before cell
infection. For ﬂuorocytometric assay 15 million cells were infected
at 37 °Cwith 2000 TCID50 of SIVsmH4i, SIVsmH4iNef+ or SIVsmE543-
3 in 8 ml of growth medium supplemented with 15 μg/ml of DEAE-
dextran. After a 6 hour incubation, the cell suspension was diluted
with 12 ml of growth medium and incubated at 37 °C in parallel with
mock-infected M7-Luc cells as a control. All infections were done in
parallel in triplicate. Approximately two million cells from eachsample were tested at 68 h post-infection. Cells were pelleted by low
speed centrifugation, washed with PBS, resuspended in 200 μl of Stain
Buffer (BD Pharmigen) and stained with anti-human CD4-APC, anti-
human HLA-A2-PE and 7-amino-actinomycin D (7-AAD) at 4 °C for
30 min. After staining cells were washed once with 2 ml of Stain
Buffer, once with 2 ml of PBS containing 5 μl/ml actinomycin D
(Sigma, Saint Louis, MO), resuspended in 100 μl of this solution and
ﬁxed by adding 20 μl of 2% formaldehyde in PBS. Live infected cells
were gated as EGFP positive and 7-AAD negative, and the percentage
of infected cells population in the MHC-I low or CD4 low gates were
measured to compare with MHC-1 high and CD4 high mock-infected
M7-Luc cells collected on the same time.
All antibodies were obtained from BD Biosciences except CD8 beta
(Beckman Coulter, Fullerton, CA) and stained cells were analyzed
by four-color ﬂow cytometry using a FACSCalibur (BD Biosciences).
Data acquisition and analysis were performed using CellQuest (BD
Biosciences) and Flowjo (TreeStar, San Carlos, CA) software.
Detection of SIV-speciﬁc antibody responses
Serology for antibodies to SIV was performed by Western blot
analysis, as previously described (Hirsch et al., 1995). Neutralizing
antibodies (Nabs) were measured as reductions in Luc reporter gene
expression in TZM-bl cells after infection with various SIVsm viruses
pre-incubated with macaque serum samples as described previously
(Monteﬁori, 2004). This assay is a modiﬁed version of the assay used
by Wei et al. (Wei et al., 2003). Brieﬂy, 50 TCID50 of virus was
incubated with various dilutions of test samples (starting with 1 to 20
with eight threefold stepwise dilutions) in triplicate for 1 h at 37 °C in
a total volume of 100 µl growth medium in 96-well ﬂat-bottom
culture plates (Corning-Costar). Freshly trypsinized cells (10,000 cells
in 100 µl of growth medium) were added to each well. One set of six
control wells received cells plus virus (virus control), and another set
of six wells received cells only (background control). Approximately
36 h after incubation, a culture medium was removed from each well
and 50 µl of Cell Lysing Buffer (Promega) was added to the cells. After
a 15 min incubation at room temperature to allow cell lysis, 30 µl of
cell lysate was transferred to 96-well black solid OptiPlates-96F plates
(PerkinElmer) for measurements of luminescence using a Mithras
LB940 luminometer (Bethold Technologies)) that inject luciferase
assay substrate (Promega) into each well. The 50% inhibitory dose
(ID50) was deﬁned as the serum dilution that caused a 50% reduction
in luciferase activity compared to virus control wells after subtraction
of background. To calculate the dilution of serum that neutralized 50%
of infectious virus (ID50), the inhibitory dose–response curve was ﬁt
with a nonlinear function (a four-parameter dose–response curve
equation) using GraphPad Prism 5 software (GraphPad Software,
Inc.).
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